Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection


This technology describes recombinant viruses that have weakened ability to establish and/or maintain latency and their use as live vaccines. The viruses have one or more genetic mutations that allow for continued replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the virus that causes chickenpox and whose latent infection results in shingles, a condition that affects up to an estimated 1 million people per year in the United States alone. Additionally, there are veterinary applications of this technology. Specific examples of gene deletions, modifications, and/or insertions are described. Furthermore, replacement of these deleted genes with other desirable viral antigen encoding sequence(s) and/or cytokine genes in order to enhance a desired immunological response is also described. Aspects of this technology are relevant to other live virus vaccines, thus increasing the safety of such vaccines.

Inventors:

Jeffrey Cohen (NIAID)  ➽ more inventions...

Lesley Pesnicak (NIAID)  ➽ more inventions...

Edward Cox (NIAID)  ➽ more inventions...


Intellectual Property:
PCT Pat: 8,916,175 issued 2014-12-23
US Application No. 60/583,399 filed on 2004-06-29
US Application No. 11/630,147 filed on 2008-01-03

Licensing Contact:
Peter Soukas, J.D.
Email: peter.soukas@nih.gov
Phone: 301-496-2644

OTT Reference No: E-217-2004-0
Updated: Jul 9, 2013